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Abstract
OBJECTIVES: Pneumonectomy with en bloc chest wall resection is often denied because of the procedure-related high risk. We evalu-
ated the short- and long-term outcome of this procedure.
METHODS: From January 1995 to October 2011, 34 patients (30 males and 4 females; mean age: 61.8 years) underwent pneumonec-
tomy with en bloc chest wall resection for 33 non-small-cell lung cancer and 1 metastatic osteosarcoma in two institutions. Data were
retrospectively reviewed.
RESULTS: Operative (30-day) mortality was 2.9% (1 of 34), and morbidity was 38.2% (13 of 34). There were 14 (41.1%) right-side proce-
dures and 20 (58.8%) left-side procedures. Three (8.8%) patients developed bronchopleural ﬁstulas. The mean number of resected ribs
per patient was 2.7 ± 1.1. In 13 (38.2%) patients, a prosthetic reconstruction of the chest wall was needed. In 3 (8.8%) cases, the bron-
chial step was buttressed. Preoperative pain was statistically signiﬁcantly related to the depth of chest wall invasion (P = 0.026). The N
status was N0 in 18 (52.9%) cases, N1 in 9 (26.4%), N2 in 6 (17.6%) and Nx in 1 (metastatic osteosarcoma). Patients were followed-up
for a total of 979 months. The median survival was 40 months. The overall 5-year survival was 46.8% (±95% conﬁdence interval [CI]:
0.2–0.6): 45.2 (±95% CI: 0.03–0.8) for right-side and 48.4% (±95% CI: 0.2–0.7) for left-side procedures, respectively. According to the N
status, the 5-year survival was 59.7 (±95% CI: 0.3–0.8) in N0, 55.5 (±95% CI: 0.06–1) in N1 and 16.6% (±95% CI: 0–0.4) in N2. The
subgroup N0 plus N1 (27 patients) showed a 58.08% (±95% CI: 0.3–0.8) 5-year survival compared with 16.6% (±95% CI: 0–0.4) in N2
(χ2: 3.7; P = 0.053).
CONCLUSIONS: Pneumonectomy with en bloc chest wall reconstruction can be safely offered to selected patients. The addition of en
bloc chest wall resection to pneumonectomy does not affect operative mortality and morbidity compared with standard pneumonec-
tomy. The pivotal additional effect of the chest wall resection should not be considered a contraindication for such procedures. Survival
showed a clinically relevant difference by comparing N0 plus N1 with N2 (58.1 vs 16.6%), not conﬁrmed by the statistical analysis
(P = 0.053).
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INTRODUCTION
Pneumonectomy with en bloc chest wall resection is a rarely per-
formed procedure because of the high perioperative surgical risk,
which is related either to the pneumonectomy itself or to the re-
section of the chest wall, and to the combined effect of both pro-
cedures. The additional impairment of respiratory function related
to the combined procedure is as high as 27% as highlighted in a
recent paper from Memorial Sloan Kettering Cancer Center, NY,
USA [1]. Most of the papers addressing the issue of pneumonec-
tomy with chest wall resection conclude that this procedure should
be performed only in highly selected patients [1–6] and should not
be routinely recommended. Such negative attitude denies some
patients the chance of a potentially radical and curative procedure.
Nevertheless, the total number of reported patients in the literature
is very small, there are no clear data and no study on such topics
exists up to now. In this paper, we sought to evaluate morbidity
and mortality and the outcome of pneumonectomy with en bloc
chest wall resection in a case series of 34 patients coming from two
high-volume Italian institutions.
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MATERIALS AND METHODS
From January 1995 to October 2011, 34 patients (30 males and 4
females; mean age: 61.8 years, range 19–78) underwent pneu-
monectomy with en bloc chest wall resection, out of a total
of 715 pneumonectomies performed in the same period (4.7%),
in two Italian institutions, Carlo Forlanini Hospital, Azienda
Ospedaliera San Camillo Forlanini, Rome (14 patients) and
European Institute of Oncology (EIO), Milan (20 patients).
Indications for surgery were in 33 patients with non-small-cell
lung cancer (NSCLC) and in 1 patient with metastatic osteosar-
coma. Data were retrospectively reviewed. Demographics are
shown in Table 1. Preoperative workup included chest radiog-
raphy and thoracic, abdominal and brain computed tomogarphic
(CT) scan. Positron emission tomography - computed tomo-
graphy (PET-CT) has been routinely performed since 2007.
Preoperative workup also included routine biochemical proﬁle,
bronchoscopy, pulmonary function tests and arterial blood gas
analysis at rest, as well as quantitative ventilation and perfusion
scans in patients in whom predicted postoperative forced expira-
tory volume in 1 s (FEV1) could be estimated <1 l, or 40%.
Patients with FEV1 that is greater than 80% predicted and
without evidence of dyspnoea or interstitial lung disease are con-
sidered suitable candidates for pneumonectomy without further
testing. Preoperative FEV1 and diffuse lung carbon oxide (DLCO)
values are shown in Table 2. In some cases, an exercise test
with the determination of maximum oxygen uptake (VO2) was
performed. Operative risk was considered acceptable if the
maximum VO2 was ≥20 ml/kg/min and unacceptable if it was
≤10 ml/kg/min. With values between 10 and 20 ml/kg/min,
patients were considered at relatively high risk, and deﬁnitive de-
cision was based on a complex evaluation taking into account
the predictive postoperative FEV1, PO2, PCO2, maximum VO2,
age and associated comorbidities. Mediastinoscopy was not rou-
tinely performed as part of the preoperative workup, except to
rule out an N2 disease when suspected on the basis of positive
nodes on PET-CT or enlarged mediastinal lymph nodes at CT
scan (minimum diameter >1.0 cm). Indications for surgery were
NSCLC in 33 patients and pulmonary metastasis from osteosar-
coma in 1 patient. Pneumonectomy was needed because of: (a)
bulky hilar nodal involvement (3 patients); (b) vascular involve-
ment (5 patients); (c) bilobar (trans-ﬁssure) involvement (22
patients); (d) completion pneumonectomy (4 patients). Surgical
procedures were performed through postero-lateral thoracot-
omy. The bronchus was sectioned with a bronchial stapler in 33
cases (TA™ 30: 20 patients; TA55: 7 patients and EndoGIA™: 6
patients; Covidien, Norwalk, CO, USA). Systematic lymph node
dissection was completed in all but 1 patient. NSCLC was staged
according to the 7th edition of the America Joint Cancer
Committee (AJCC) Cancer Staging TNM AJCC Cancer Staging
Handbook: TNM Classiﬁcation of Malignant Tumours. According
to the new staging system, the descriptor Pleura (PL) was used
for the evaluation of the depth of chest wall invasion: PL3 that
indicates parietal pleura involvement was substaged into: (a) par-
ietal pleura only; (b) parietal pleura + soft tissue; (c) bone invasion
(full thickness involvement) [7, 8]. According to Shapiro et al. [9],
major morbidity was deﬁned as pneumonia, adult respiratory
distress syndrome, empyema, sepsis, bronchopleural ﬁstula (BPF),
pulmonary embolism, ventilator support beyond 48 h, myocar-
dial infarct, reoperation for bleeding and central neurological
event. Hospital mortality was deﬁned as death during the same
hospitalization or within 30 days of the procedure. Informed
consent was obtained from all patients.
Statistics
We retrospectively reviewed the medical records of these
patients. Continuous variables are presented as mean ± standard
deviation unless otherwise noted. For univariate analysis, χ2 test
of the potential risk factors for postoperative complications was
performed. Survival data were complete for all patients. Survival
rates were calculated either from the date of surgery until death
or from the date of the last follow-up by means of the Kaplan–
Meier test and compared by using the log-rank test for univari-
ate analysis. A P-value of ≤0.05 was considered signiﬁcant.
RESULTS
Preoperative pain (Table 2) was statistically signiﬁcantly related
to the depth of chest wall invasion (P = 0.026), with 12 of 26
(46%) symptomatic patients being in substage ‘PL3 c’ (full thick-
ness invasion of the chest wall). Fourteen patients underwent in-
duction chemotherapy (41.1%). The mean hospital stay was
11.5 ± 4.8 (range: 6–24) days. The overall operative (30 days)
mortality was 2.9% (1 of 34). The cause of the reported death
was an early BPF complicated by respiratory insufﬁciency and
sepsis. Major morbidity was 38.2% (13 of 34; Table 3). The inci-
dence of early BPF was 2 of 34 (5.8%). Furthermore, 1 patient
developed a late BPF 226 days after the surgical procedure. An
Table 1: Demographics
Sex
Male 30
Female 4
Mean age (range) 61.8 (19–78) years
Side
Right 14
Left 20
Smokers
Active ex-smoker 31
No 3
Table 2: Preoperative data
Preoperative FEV1
80–100% 23
60–79% 9
52–59% 2
Preoperative DLCO
80–100% 17
60–79% 12
52–59% 5
Preoperative pain
Yes 26 (a: 6; b: 8; c:12)
No 8
FEV: forced expiratory volume in 1 s; DLCO: diffuse lung carbon
oxide.
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R0 resection was performed in 32 of 34 (94.1%) cases. A right-
side pneumonectomy was performed in 14 (41.1%) patients,
with an operative mortality rate of 7.1% (1 of 14). A left-side pro-
cedure was performed in 20 (58.8%) patients, with no mortality.
The histological report with the depth of chest wall invasion is
shown in Table 4. The mean number of resected ribs per patient
was 2.7 ± 1.1, and ranged from 1 to 5 (Table 4). In 13 (38.2%)
patients, a prosthetic reconstruction of the chest wall was
needed (Table 5): in 6 of 14 (42.8%) right-side procedures and in
7 of 20 (35%) left-side procedures. The most common prosthesis
employed in our series (4 of 13) was bovine pericardium
(Veritas, Synovis Life Technologies is a wholly owned subsidiary
under Baxter International, Inc., USA). In 3 (8.8%) cases, the
bronchial step was buttressed (Table 6). Thirty-one (94.1%)
patients were active or ex-smokers (Table 1). Induction therapy
did not show any statistically signiﬁcant correlation with
morbidity or with the need of postoperative ventilation. No stat-
istically signiﬁcant correlation was found between preoperative
FEV1 and the morbidity rate. Smoking habits failed to show any
statistically signiﬁcant effect on postoperative complications of
these cases and on the need for invasive postoperative ventila-
tion. The N status was N0 in 18 (52.9%) cases, N1 in 9 (26.4%),
N2 in 6 (17.6%) and Nx in 1 (metastatic osteosarcoma). Patients
were followed up for a total of 979 months. The median survival
was 40 months. The overall 5-year survival was 46.8% (±95%
conﬁdence interval [CI]: 0.2–0.6; Fig. 1): 45.2 (±95% CI: 0.03–0.8)
for right-side and 48.4% (±95% CI: 0.2–0.7) for left-side proce-
dures, respectively (no statistically signiﬁcant difference).
According to the N status, the 5-year survival was 59.7 (±95% CI:
0.3–0.8) in N0, 55.5 (±95% CI: 0.06–1) in N1 and 16.6% (±95% CI:
0–0.4) in N2. The subgroup N0 plus N1 (27 patients) showed a
58.08% (±95% CI: 0.3–0.8) 5-year survival compared with 16.6%
(±95% CI: 0–0.4) in N2 (χ2: 3.74; P = 0.05). According to the
depth of chest wall invasion, the 5-year survival was 47.6 (±95%
CI: 0.1–0.8), 43.2 (±95% CI: 0.02–0.8) and 43.7% (±95% CI: 0–0.8),
respectively, in substages PL3 a, PL3 b and PL3 c; no statistically
signiﬁcant difference was found.
Table 4: Pathological report
Chest wall resection
1 rib 4
2 ribs 12
3 ribs 11
4 ribs 4
5 ribs 3
Depth of chest wall invasion (PL3)
a 12
b 9
c 13
T staging
T4 6
T3 28
N staging (33 of 34)
N0 18
N1 9
N2 6
Histology
Adenocarcinoma 13
Pleomorphic carcinoma 3
Squamous cell carcinoma 11
Adenosquamous carcinoma 2
Large-cell carcinoma 2
Large cell neuroendocrine carcinoma 1
Mixed sarcomatoid-large-cell carcinoma 1
Metastatic osteosarcoma 1
Table 5: Prosthetic reconstruction
Veritas (bovine pericardium) 4
Gore-Tex (polytetrafluoroethylene) 3
Vicryl (polyglactin) 3
Marlex (crystalline polypropylene and high-density
polyethylene—HDPE) + methacrylate mesh
2
Marlex + polyethylene mesh 1
Table 6: Bronchial buttress
Pericardial flap 1
Diaphragmatic flap 1
Mediastinal fat 1
Table 3: Morbidity
Atrial fibrillation 3
Bronchopleural fistula 1
Bronchopleural fistula + sepsis 1
Bleeding 1
Renal failure 1
Atrial fibrillation + myocardial infarction 1
Neurological disorder 2
Cardiac failure 1
Respiratory insufficiency + cardiac failure 1
Respiratory insufficiency 1
Figure 1: Overall survival curve.
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DISCUSSION
Pneumonectomy with en bloc chest wall resection has been
seldom, if ever, reported in chest wall resection series with
unclear data and a negative attitude. Doddoli et al. [7], out of a
multicentre series of 309 NSCLC invading chest wall, reported 79
pneumonectomies, but the majority of these cases underwent
extrapleural resection and not en bloc resection. Nevertheless,
the overall mortality of the pneumonectomy group with extra-
pleural resection was remarkable: 12.7%. In a series of 107
NSCLC invading chest wall recently reported by Lee et al. [6], 45
pneumonectomies were performed, but the authors did not
identify how many chest wall resections or extrapleural dissec-
tions were performed: an impressive 57% 1-year mortality was
reported in the pneumonectomy group. Pneumonectomy itself
showed to be a univariate prognostic factor for survival in the
series (P = 0.041), and the authors concluded that pneumonec-
tomy should be avoided whenever possible because not only
cancer-related death but also respiratory-related death is signiﬁ-
cantly high. The present paper represents a unique effort to
address the outcome of patients undergoing pneumonectomy
with en bloc chest wall resections. The overall operative mortality
in our series was 2.9% (1 of 34), a ﬁgure which compares favour-
ably with the 8.5% mortality rate reported out of 1507 patients
undergoing this procedure from the Commission on Cancer of
the American College of Surgeons national hospital survey per-
formed in 2001, and with the 5.6%, out of 1002 patients, recently
reported by Shapiro et al. from the Society of Thoracic Surgeons
(STS) database [9, 10]. It should be stressed that the selection bias
of both multicentre series reported by the ACS and the STS
which also include procedures performed by general surgeons
and cardiovascular surgeons and may justify the higher mortality
rates compared with board-certiﬁed thoracic surgeons series
[8, 9, 10]. The overall morbidity in our series was 38.2% (13 of
34), a percentage which is in line with the 30.4% reported from
the STS database [9]. It is well known that pneumonectomy itself
is associated with the highest degree of pulmonary and function-
al status compromise [11–13]. Additional chest wall resection
could potentially worsen pulmonary reserve in such patients and
be the single most important factor for understanding the mor-
bidity rate [14]. In our series, no statistically signiﬁcant correlation
was found between preoperative FEV1 and DLCO, and the mor-
bidity rate. The bias of such observation is the selection criteria
of our series, including a high number of patients with a normal
or border-line respiratory function: 67.6% of our patients (23 of
34) had an FEV between 80 and 100%, and only 2 (5.8%) had an
FEV1 <60% [15]; furthermore, 85.2% (29 of 34) had a preopera-
tive DLCO value >60%. In our series, the extent of chest wall
resection did not impact the morbidity rate: most of the proce-
dures undertook the resection of two or three ribs (12 vs 11
patients, respectively). In agreement with Doddoli et al.’s series
[7], we found no statistically signiﬁcant difference between the
two groups (two vs three ribs resection) in terms of morbidity
and mortality rate. The overall 5-year survival in our series was
46.8% (±95% CI: 0.2–0.6; Fig. 1). Survival was not affected by the
side of the resection. According to the N status, survival was
59.7% (±95% CI: 0.3–0.8) in N0, 55.5% (±95% CI: 0.06–1) in N1
and 16.6% (±95% CI: 0–0.4) in N2. Comparing the N2 group with
the N1 plus N0 group (16.6%; ±95% CI: 0–0.4) vs (58.08%; ±95%
CI: 0.3–0.8, P = 0.053), the N2 status failed to be a statistically sig-
niﬁcant prognostic factor even if the P-value was very close
(Fig. 2). In conclusion, pneumonectomy with en bloc chest wall
reconstruction can be safely offered to selected patients. The
addition of en bloc chest wall resection to pneumonectomy does
not affect operative mortality and morbidity compared with
standard pneumonectomy. The pivotal additional effect of the
chest wall resection that jeopardizes the feasibility of the com-
bined procedure should not be taken into account in approach-
ing such operation in the light of the results reported in the
present series. A careful knowledge of comorbidity and cardio-
respiratory function can help to identify patients who are at
increased risk for unfavourable outcomes. The critical factor is
the experience of the institution in dealing with such complex
resections. Survival is related to the nodal status. Large data are
needed for a better evaluation of pneumonectomy with en bloc
chest wall resection.
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APPENDIX. CONFERENCE DISCUSSION
Dr P. Van Schil (Antwerp, Belgium): In this retrospective study from 1995
until 2011, 34 patients underwent pneumonectomy with en bloc chest wall
resection. Thirty-day mortality of these very extensive operations was only 3%
and morbidity was 38%. Overall median survival time was 40 months. The
authors nicely demonstrate that these demanding interventions can be per-
formed safely in selected patients in centres having a large experience with
difﬁcult thoracic surgery. I have two questions. In 14 patients, or 41%, induc-
tion chemotherapy was given. What were the precise indications for induc-
tion chemotherapy, and how was restaging performed?
Second, looking at your last conclusion, mediastinoscopy was only select-
ively used in this study. Pathological N2 disease was found in almost 18% of
patients. What were the speciﬁc sites of N2 involvement? As N2 disease is a
major negative prognostic factor, should mediastinoscopy not routinely be
performed in this subset of patients before embarking on such a large
resection?
Dr Cardillo: I prefer to answer the second question ﬁrst. First of all, I want
to clarify that the surgical staging of the mediastinum is mandatory in patients
undergoing such a big operation. It doesn’t matter how you do the surgical
staging; it can be done by mediastinoscopy or by EBUS or by EUS. The most
important factor is to stage the mediastinum. After we stage the mediastinum,
we have to understand how we analyse the results, if it is a single zone or if it
is multiple zone involvement. In single zone N2 disease, maybe a procedure
can be done. Out of the six patients who had N2 disease, we found two
patients with single zone N2 disease and in such patients we ﬁrst performed
the surgical procedure.
As regards postoperative therapy, according to our rule we very often give
induction therapy in every patient with N2 disease. This is our rule. It doesn’t
matter if it is a single zone or a multiple zone. But in a patient with such
major disease for which the alternatives are very few, maybe in the MDT
meeting that should take place before the operation, even the single zone
patient can undergo surgery. So the answer to the induction therapy is that
we offer induction whenever there is single zone N2 disease; that is manda-
tory for us. But there are some points that should be discussed within the
MDT, for example, single zone N2 disease. That is because we had six patients
with N2 disease. Maybe in the near future when we further analyse the
results of this study, we should be much more careful in offering this proced-
ure to an N2 patient even if it is a single zone because of the high periopera-
tive morbidity, although the mortality was very low. The lesson that we
should take home is that whenever there is N2, single zone or multiple zone,
it is better to deny the operation because the result is not good and because
of the perioperative risk.
Dr Van Schil: Would you also consider induction therapy in patients with
large-volume tumours to obtain a downstaging and probably to have a lesser
extent of chest wall resection?
Dr Cardillo: Yes, but I think that in these patients, we have to consider the
issue of the pain. These patients have a lot of pain and sometimes it is very
difﬁcult, even with ﬁrst-class painkillers such as oral morphine, to control
pain. These patients will ask for treatment even if they know that the results
are not good.
Dr A. Chapelier (Suresnes, France): I have a comment and two questions.
First, we at Marie Lannelongue in 2000 reported that for T3 lung cancer, the
depth of chest wall involvement was a signiﬁcant prognostic factor. My ques-
tion is, for such an important resection, did you analyse this factor, the depth
of chest wall involvement, in the survival?
Dr Cardillo: Yes. As I showed in one of my slides, we divided the PL3 factor
(the level of the pleural involvement is called PL); PL3 means involvement of
the parietal pleura. We divided PL3 into A, B, and C: PL3A means parietal
pleura only, PL3B parietal pleura plus soft tissue, and PL3C, full-thickness. We
found no statistically signiﬁcant difference in this subset of patients. But it
depends on the number of patients. In a previously published paper from
Carlo Forlanini Hospital in Rome ( J Thorac Cardiovasc Surg 2001;121;649), we
have shown a difference between the different levels of chest wall involve-
ment and survival. So it depends on the number of patients included in the
study. This study involves only 34 patients whereas in our previous paper
addressing the T3 group, the number was over 100, and we found a differ-
ence. We found no difference here maybe because the number was small for
such a major and rare operation.
Dr Chapelier: Second, what is the rationale for chest wall reconstruction
after this operation? You mentioned that a third of the patients had chest
wall reconstruction.
Dr Cardillo: The rule for chest wall reconstruction is the same as every op-
eration dealing with chest wall resection after lung cancer. It depends on the
level of the chest wall involvement. For example, if the scapula can cover the
defect, we don’t use any prosthetic graft, of course; usually up to the fourth
rib, we never use a prosthetic graft. When the defect is in the anterior part of
the chest wall or is below the ﬁfth rib, in that case we use prosthetic grafts.
Usually we use a Gore-Tex soft tissue patch or, as we did most recently, we
moved toward the biological patch, the Veritas bovine pericardial patch.
These are the most commonly used in our experience.
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